L-Glutamic Acid
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH OLAO
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 75N98026Q01122 in this department, oldest first.
- Aug 31, 2026Combined Synopsis/SolicitationOpen
- Aug 31, 2026 · this noticeCombined Synopsis/Solicitation
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Decide bid or no bid before the response deadline.
- Look at the past winners for likely competitors and teaming partners.
- Follow the opportunity to hear about amendments and the award.
What the notice says
NON-COMPETITIVE COMBINED SYNOPSIS / SOLICITATION Title: L-Glutamic Acid (i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98026Q01122 / PCA-NIMH-04010. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract… (show all)
or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed price on a non-competitive basis to Sigma-Aldrich Inc., 3050 Spruce St., Saint Louis, Missouri 63103 for the requested L-Glutamic Acid (2,4 ��C2-99%). (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2026-01 dated March 13, 2026. (iv) The associated NAICS code is 325180 � Other Basic Inorganic Chemical Manufacturing, and the small business size standard is 1,000 in number of employees. This requirement is not a set-aside for small business. (v) Description of Requirement: This requirement is to obtain a special Sigma-Aldrich Inc., 13C2 L-Glutamic Acid 2,4 99%,1x1 gram. The Magnetic Resonance (MR) Spectroscopy Unit and Core have been conducting several in vivo carbon-13 (1*3C) spectroscopy projects with infusion of 13C labeled chemicals. Because natural abundance of 1*3C is only 1% and is too weak to be detected. Therefore, we need to use chemicals with enriched 13C to increase 13C signal intensity. With these 13C labelled chemicals, we will be able to detect brain metabolism and to accurately measure the concentrations of several important metabolites. The 13C MR spectroscopy methods developed in our group is and will be applied to many other research groups in NIMH and NIH for various neural science studies. Without this chemical, the institute will lose a powerful method in neural science research. (vi) Delivery Location: NIH, NIMH, 10 Cener Drive, Bldg. 10, Bethesda, MD 20892 (vii) [Reserved, if needed] (viii) FAR 52.204-7, System for Award Management, applies to this acquisition. (ix) The provision at FAR 52.212-1, Instructions to Offerors�Commercial Items, applies to this acquisition. Add any additional instructions as required. (x) The provision at FAR 52.212-2, Evaluation�Commercial Items, applies to this acquisition. (a) A written notice of award or acceptance of an offer, issued to the successful offeror within the time specified in the offer, shall result in a binding contract without further action by either party. The Government reserves the right to accept any offer (or part of an offer) before the expiration date, whether or not discussions are conducted, unless a written notice of withdrawal is received prior to award. (xi) FAR 52.212-4, Contract Terms and Conditions�Commercial Items, applies to this acquisition. (xii) Additional contract requirements or terms and conditions, as determined necessary by the Contracting Officer and consistent with customary commercial practices: None. (xiii) The Defense Priorities and Allocations System (DPAS) is not applicable to this requirement. (xiv) Submission Requirements: Responses must include sufficient information to demonstrate the respondent�s capability to provide the required product or service. Price quotations shall include, at a minimum: unit price, list price, shipping and handling costs, delivery timeframe after award, delivery terms, prompt payment discount terms, F.O.B. point (destination or origin), product or catalog numbers, product descriptions, and any other relevant information. Evaluation factors may include, but are not limited to: past performance, technical capability, price, delivery, special features, trade-in considerations, expected lifecycle, warranty, maintenance availability, and environmental or energy efficiency considerations. Respondents claiming to be manufacturers or authorized resellers of a specified brand-name product must provide: (a) Product, catalog, model, and/or part number(s); (b) Product description; (c) Documentation demonstrating that the offered item meets all required salient characteristics; (d) Quantity; (e) Estimated price or cost; (f) Shipping, handling, and/or installation charges; and (g) Delivery timeframe after receipt of order. Responses must also include the Unique Entity Identifier (UEI), Taxpayer Identification Number (TIN), and business size certification. All offerors must be actively registered in the System for Award Management (SAM) at www.sam.gov. All responses must be received by Tuesday, September 8, 2026 @ 10:00 AM eastern daylight time (EDT) and must reference announcement / solicitation number: 75N98026Q01122 / PCA-NIMH-04010 with response submitted electronically to email address of tonia.alexander@nih.gov. Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f). (xv) Point of Contact: Tonia Alexander, at tonia.alexander@nih.gov.
Who won similar work
258 award notices on SAM.gov in the last 24 months. Match: Same agency (National Institutes of Health), any industry: a loose match.
Loose match: same agency, any industry. Read the titles before treating these as competitors.
| Winner | Awards | Value | Last |
|---|---|---|---|
| BECTON, DICKINSON AND COMPANY · $BDX | 4 | $1.9M | Jan 26, 2026 |
| DUKE UNIVERSITY Durham NC 27705 USA | 3 | $36.3M + 1 shared | Dec 21, 2025 |
| Axle Informatics Rockville MD 20852 USA | 3 | $24.5M | May 22, 2025 |
| Axle Informatics, LLC | 3 | $15.4M | Dec 15, 2025 |
| BRUKER BIOSPIN CORP · $BRKR | 3 | $1.7M | Jul 30, 2026 |
| AGILENT TECHNOLOGIES INC · $A | 3 | $445K | Jul 24, 2025 |
| GOVERNMENT SCIENTIFIC SOURCE INC | 3 | $318K | Jan 9, 2026 |
| Multiple_Awards Bethesda MD USA | 2 | $1.1B | Dec 17, 2024 |
| FISHER BIOSERVICES INC | 2 | $148.0M | Oct 7, 2026 |
| Coriell Institute for Medical Research, Inc. | 2 | $58.8M | Aug 1, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in.
- Oct 9, 2026Revvity Health Sciences, Inc.$21KAutomated Cell Counter and Analyzer
- Oct 7, 2026PPD DEVELOPMENT LP$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026FISHER BIOSERVICES INC$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026BCG FEDERAL CORP.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026ADVANCED BIOSCIENCE LABORATORIES, INC.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026SIA PARTNERS U.S., INC.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026AMERICAN TYPE CULTURE COLLECTION Manassas VA 20110 USA$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Sep 30, 2026Washington Metropolitan Area Transit Authority Washington DC 20024 USA$23.8MNIH TRANShare Program -WMATA SmartBenefits� Program Transit Benefit Services
- Sep 29, 2026THE BROAD INSTITUTE, INC$215KWhole genome sequencing for investigation of age-related chronic disease in HANDLS participants
- Sep 28, 2026EMORY UNIVERSITY 1599 CLIFTON ROAD NE 4TH FLOOR MAILSTOP 1599-001-1BA Atlanta GA 30322 USA$7.4M (shared ceiling)A--Recipient Epidemiology and Donor Evaluation Study
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (0 filings)
- 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
- $45K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Energy and Commerce, Senate Committee on Appropriations, Senate Committee on Health, Education, Labor, and Pensions
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards.
- 3 of the past winners are listed companies
- 0 insider buys and 5 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.